Appointment of Investor Relations Adviser

Genflow replaces its IR adviser, highlighting ongoing clinical programs and sector focus.

What the company is saying

Genflow Biosciences Plc has appointed ON365 Partners Inc. as its new investor relations adviser, effective immediately, replacing Harbor Access. The company frames this change as a strategic move to leverage ON365's healthcare and life sciences expertise and North American investor network. The announcement emphasizes Genflow's position as an emerging leader in longevity research, referencing its centenarian SIRT6 gene therapy platform and ongoing clinical programs. Dr. Eric Leire, CEO, is quoted stressing the importance of clear communication as the company transitions from preclinical to clinical, regulatory, and commercial milestones. The company provides brief operational context, noting its lead compound GF-1002 and the start of a proof-of-concept trial in aged dogs in March 2025, as well as a planned clinical trial for MASH. The tone is confident and forward-looking, but operational and financial specifics are limited. The company thanks Harbor Access for its prior support.

What the data suggests

The only concrete data disclosed are the effective date of ON365's appointment, the March 2025 start of a proof-of-concept clinical trial in aged dogs, and the company's founding year of 2020. No financial figures, contract terms, or KPIs are provided for the IR adviser change. The announcement references ongoing and planned clinical trials but does not disclose enrollment numbers, endpoints, or timelines for results. The company's R&D presence in Belgium is confirmed. The evidence for ON365's sector expertise and investor network is asserted but not quantified. No data is provided on Harbor Access's tenure or performance. The release is procedural, with limited actionable information for investors beyond the fact of the adviser transition and the status of clinical programs.

Analysis

This announcement is a routine disclosure of a change in investor relations adviser, with ON365 Partners Inc. replacing Harbor Access. The tone is positive, but the content is factual and procedural, with no exaggerated claims or promotional language regarding the company's prospects. While there are brief mentions of ongoing and planned clinical programs, these are not the focus and are described in neutral terms without unsupported projections or hype. No financial, operational, or profitability metrics are disclosed, but this is appropriate for a personnel/IR appointment release. The forward-looking statements are limited to general aspirations about ON365's potential support and a mention of a future clinical trial, neither of which are overstated or central to the announcement. There is no evidence of capital intensity or long-dated, uncertain returns being paired with promotional language.

Risk flags

• ●There is no disclosure of the terms, duration, or performance metrics for ON365's engagement, making it difficult to assess the potential impact or cost of the adviser change. This opacity limits investor ability to evaluate whether the new adviser can deliver improved outcomes.
• ●The announcement provides no quantitative updates on clinical trial progress, enrollment, or results, so the status and prospects of Genflow's lead programs remain unclear. This lack of detail increases uncertainty about near-term value creation.
• ●Forward-looking statements about ON365's sector focus and North American network are not supported by evidence or specific targets, introducing execution risk if the adviser does not deliver expanded investor engagement as anticipated.

Bottom line

This is a routine IR adviser replacement with no disclosed financial terms or operational impact. The announcement serves to reassure investors that Genflow is seeking broader investor engagement as it advances its gene therapy programs, but provides no new data on clinical progress or financial health. The credibility of the narrative rests on ON365's asserted sector expertise, which is not substantiated with evidence in the release. Investors should not expect immediate effects from this change, and the most important takeaway is that Genflow's clinical and commercial progress, not its IR adviser, will determine future value. Further updates with concrete clinical or financial milestones would be required to materially change the investment case.

Announcement summary

(LSE:GENF) (OTCQB:GENFF) Genflow Biosciences Plc announced the appointment of ON365 Partners Inc. as the Company's investor relations adviser, with immediate effect. ON365 succeeds Harbor Access, which has supported the Company's investor relations activities to date. ON365 is a specialist investor relations and strategic advisory firm focused on the healthcare and life sciences sector, providing capital markets counsel, investor engagement and corporate communications support to publicly listed companies. Genflow believes that ON365's sector focus and North American investor network will support Genflow as it advances its centenarian SIRT6 gene therapy platform and broadens its dialogue with institutional and retail investors across its listings. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Genflow is headquartered in the UK with R&D facilities in Belgium. The Company thanks Harbor Access for its contribution to Genflow's investor relations programme and wishes the team well.

Disagree with this article?